Navigation Links
Psoriasis Cure Now Welcomes Institute of Medicine Report Urging 'Comparative Effectiveness' Research on Psoriasis, But Worries About Risk of Rationing

KENSINGTON, Md., June 30 /PRNewswire-USNewswire/ -- "Psoriasis Cure Now," a nonprofit patient advocacy group, today applauded the Institute of Medicine (IOM) for including psoriasis and psoriatic arthritis among its Top 100 health topics meriting priority "comparative effectiveness" research, but the organization expressed concern that treatment rationing could result from the research.

The IOM included the use of biologics for treating inflammatory diseases including psoriatic arthritis among its top ("First Quartile") priorities for the first round of comparative effectiveness research, and included comparing the effectiveness of various treatments for psoriasis among its Second Quartile priorities. According to the IOM, "A committee convened by the IOM developed the list of priority topics at the request of Congress as part of a $1.1 billion effort to improve the quality and efficiency of health care through comparative effectiveness research outlined in the American Recovery and Reinvestment Act of 2009."

"We applaud the IOM committee for including treatments for psoriasis and psoriatic arthritis among its priority research areas, as it can be very challenging for patients with these lifelong diseases to navigate their myriad treatment options, each of which has its own set of short and long-term risks," said Michael Paranzino, president of Psoriasis Cure Now. "But as with most things in life, the devil is in the details. Comparative effectiveness research requires assigning extremely controversial dollar amounts to various levels of patient improvement, and also assigns monetary values to various levels of risk of side-effects, even though a 25 year-old mother and a 70 year-old man might have very different levels of willingness to risk serious side-effects. Today's comparative effectiveness research can very easily become tomorrow's rationing mandate."

Paranzino continued, "Different psoriasis treatments vary widely in cost, effectiveness, and side-effects. Some patients will trade less effectiveness for fewer side-effects. Others will accept serious long-term risks to feel better now. In addition, some psoriasis treatments cause catastrophic birth defects if given to women who become pregnant while taking them, but help men without these risks. In short, for a researcher to conclude that Treatment A helps an 'average' patient improve for less money than Treatment B, that researcher must make assumptions that may fly in the face of reality for real patients in real-world circumstances.

"It is essential that patient voices be heard throughout the actual comparative effectiveness research, or else this could become just a fancy way to deny advanced, but costly, treatments to people with serious but incurable diseases like psoriasis."

For more information on psoriasis, visit the Psoriasis Cure Now homepage at

SOURCE Psoriasis Cure Now
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Source of Information on Psoriasis Medications
2. Psoriasis Raises Risk of Heart Attack, Stroke, Death
3. American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications
4. Psoriasis Patients Happy With Home-Based Treatment
5. Study Results Published in CUTIS Demonstrate Long-Term Safety and Efficacy of Vectical(TM) (calcitriol) Ointment 3 mcg/g in the Management of Mild-to-Moderate Plaque Psoriasis
6. Having Psoriasis Raises Risk of Diabetes, Hypertension
7. Psoriasis Drug Raptiva Pulled From U.S. Market
8. Low-Dose Acitretin May Reduce Nail Psoriasis
9. BioTrends Prepares to Field ChartTrends(TM) Reports to Cover the Use of Biologic Agents in Psoriasis and Rheumatoid Arthritis
10. LeAnn Rimes Shares Her Personal Struggle With Psoriasis in Nations Capital
11. Study Shows Nonprescription LCD Topical Solution is More Effective than Prescription-Strength Calcipotriol Cream for Moderate Plaque Psoriasis
Post Your Comments:
(Date:6/27/2016)... NY (PRWEB) , ... June 27, 2016 , ... ... using cutting edge technology to revolutionize the emergency ambulance transport experience for the ... are aware of how Uber has disrupted the taxi industry through the use ...
(Date:6/26/2016)... Carolina (PRWEB) , ... June 26, 2016 , ... ... of a new product that was developed to enhance the health of felines. The ... centuries. , The two main herbs in the PawPaws Cat Kidney Support ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 ... brings up a new, often overlooked aspect of head lice: the parasite’s ability to live ... not a common occurrence, but a necessary one in the event that lice have simply ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... On Friday, ... presented a Bronze Wellness at Work award to iHire in recognition of their exemplary ... part of the 7th annual Maryland Workplace Health & Wellness Symposium at the BWI ...
(Date:6/24/2016)... ... , ... Marcy was in a crisis. Her son James, eight, was out of control. Prone ... physically. , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If ... at my other children and say he was going to kill them. If we ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... June 24, 2016   Bay Area Lyme ... Dean Center for Tick Borne Illness , ... Rehabilitation, MIT Hacking Medicine, University of California, Berkeley, ... announced the five finalists of Lyme Innovation ... More than 100 scientists, clinicians, researchers, entrepreneurs, and ...
(Date:6/24/2016)... Calif. , June 24, 2016  American Respiratory Labs (ARL), ... is now able to perform sophisticated lung assessments in patients, homes, ... , Inc. Patients are no longer limited to ... EasyOne PRO ® , ARL patients like Jeanne R. of ... in the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016  Arkis BioSciences, a leading ... and more durable cerebrospinal fluid treatments, today announced ... Series-A funding is led by Innova Memphis, followed ... other private investors.  Arkis, new financing will accelerate ... the market release of its in-licensed Endexo® technology. ...
Breaking Medicine Technology: